Dr. Richard S. Blumberg is senior physician and division chief of gastroenterology, hepatology and endoscopy at Brigham and women’s Hospital, Boston. He also serves as professor of medicine at Harvard Medical School, co-director of the Harvard Digestive Diseases Center and chair of the Brigham Research Institute. His research has been funded by the National Institutes of Health since 1989, with a focus on mucosal immunology. He received his M.D. from Jefferson Medical College. Dr. Blumberg was scientific founder and director of Syntonix Pharmaceuticals, which developed the FDA-approved drugs Eloctate and Alprolix for the treatment of hemophilia.